Tuebingen

• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat … Ended recruitment
  2023-507338-26-00 5 2021-02-01 Histologically documented gastric or gastroesophageal junction adenoca
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended recruitment
  2024-514502-31-00 5 2021-01-11 Prurigo Nodularis
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® co … Ended recruitment
  2024-518033-28-00 6 2020-11-27 Prophylaxis of transplant rejection in adult liver allograft recipient
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc … Ended recruitment
  2022-502611-10-00 5 2020-11-24 Primary Progressive Multiple Sclerosis (PPMS)
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc … Ended recruitment
  2023-506515-18-00 5 2020-10-23 Primary Progressive Multiple Sclerosis (PPMS)
• Treatment of advanced-stage malignancies harboring BRAF mutations with combination of Sorafenib and Trametinib: a multicenter study Ended recruitment
  2024-512887-77-00 9 2020-10-21 advanced-stage malignancies harboring BRAF mutations with impaired kin
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended recruitment
  2023-506467-34-00 5 2020-10-20 Relapsing Multiple Sclerosis (MS)
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended recruitment
  2024-514404-13-00 5 2020-10-01 Atopic Dermatitis
• A study of a combination of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) compared to Bortezomib with Pomalidomide and Dex … Ended recruitment
  2023-506877-37-00 5 2020-09-28 Relapsed/Refractory Multiple Myeloma
• Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio … Ended recruitment
  2024-516481-11-00 5 2020-09-22 Metastatic Castration-Resistant Prostate Cancer
• An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat … Ended recruitment
  2023-503421-19-00 5 2020-08-26 Urothelial cancer
• Reduced intensity radio-chemotherapy for stage IIA/B seminoma Ended recruitment
  2023-509663-24-00 4 2020-08-20 Stage IIA/B seminoma
• Long-term need of Ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due … Ended recruitment
  2023-507816-11-00 5 2020-08-17 Macular edema due to central retinal vein occlusion
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with ISN/RPS 2003 Class III or IV Lupus Nephritis Ended recruitment
  2023-503628-22-00 5 2020-07-16 Lupus Nephritis (LN)
• CREST - Phase 3 Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) or as a Single Agent in Participants Wi … Ended recruitment
  2023-509089-39-00 5 2020-07-01 Non-Muscle Invasive Bladder Cancer
• A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multipl … Ended recruitment
  2023-508962-14-00 5 2020-06-18 Relapsed/Refractory Multiple Myeloma
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha … Ended recruitment
  2023-506588-32-00 5 2020-06-12 Relapsed and Lenalidomide-Refractory Multiple Myeloma
• Adjuvant nivolumab treatment in stage II high-risk melanoma – A randomized, controlled, phase III trial with biomarker-based risk stratifica … Ended recruitment
  2023-509394-23-00 5 2020-06-12 Stage II melanoma arising from a primary cutaneous site after surgery
• Short course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined … Ended recruitment
  2024-511577-29-01 5 2020-03-13 intermediate and high-risk rectal cancer
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended recruitment
  2024-511653-22-00 5 2020-02-12 Cutaneous Squamous Cell Carcinoma (CSCC)

Showing 409–432 of 591 trials